Ovarian Cancer

Dr. Nicholas Vogelzang from the Comprehensive Cancer Centers of Nevada Describes Cabozantinib's side effects

Dr. Nicholas J. Vogelzang from the Comprehensive Cancer Centers of Nevada on Cabozantinib Clinical Trial Results

Long-term use of talc-based powder significantly increased the risk of invasive ovarian cancer in a large case-control study

More often than not, ovarian cancer is diagnosed at an advanced stage

Each year the National Comprehensive Cancer Network (NCCN) presents the latest updates to its Clinical Practice Guidelines in Oncology, as well as the latest cancer therapies by key opinion leaders.

The goal of personalized medicine remains in its infancy as oncologists strive to determine treatments specific to a patient's tumor characteristics

The risk of dying from ovarian cancer was not reduced when women received CA-125 blood testing and transvaginal ultrasound

Dr. Markman Discusses the Olaparib Phase II Trial

Dr. Pecora on Ovarian Cancer PARP Inhibitor for Ovarian Cancer

Oncology Nurse Fiona McCaughan on Struggles Facing Intraperitoneal Ovarian Cancer Treatments

Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer

Dr. Karlan Describes AMG 386 Side Effects Found in the Phase II Ovarian Cancer Trial

The results of a small clinical trial showed that low-level expression of a microRNA correlated with improved progression-free survival

Nektar Therapeutics announced that its oncology drug candidate, NKTR-102, has been granted orphan drug status

Analysis of the Phase II AMG 386 and Paclitaxel Combination Trial

Cervical cancer affects about 470,000 women each year and now the disease has a new tool to combat its spread

Useful Online Resources and Clinical Trials for Ovarian Cancer

Women with early-stage ovarian cancer were nearly twice as likely to die if they did not have recommended staging biopsies of pelvic and aortic lymph nodes

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

Useful Online Resources and Clinical Trials for Ovarian Cancer

The University of Glasgow will begin offering medical and scientific research findings, including cancer-related discoveries, to businesses and entrepreneurs free of charge

Worldwide, there are ~204,000 new cases of ovarian cancer each year, accounting for 4% of cancers diagnosed in women.

Screening for ovarian cancer offers limited value, especially when accounting for the disease's biological diversity.

Two separate studies show the relationship between hormone replacement therapy and women's cancers.

A US district court invalidated 7 of 23 of Myriad Genetics, Inc's patents on the BRCA1 and BRCA2 genes, which confer an increased risk of developing breast, ovarian, and prostate cancers.